Bellerophon therapeutics announces completion of enrollment in phase 3 rebuild study for inopulse® in fibrotic interstitial lung disease

Enrollment concludes earlier than anticipated; pivotal top-line data now expected mid-2023 enrollment concludes earlier than anticipated; pivotal top-line data now expected mid-2023

BLPH Ratings Summary

BLPH Quant Ranking